• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
IMVT

IMVT

Immunovant, Inc.

NASDAQHealthcareBiotechnologyUS

USD31.15

+0.23 (+0.74%)

Rating:C

Company Profile

CEO

Eric Venker

IPO Date

2019-06-21

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$30.82

Prev. Close

$30.92

Day Low

$30.33

Day High

$31.31

52W Low

$14.32

52W High

$36.28

Market Cap

$6.40B

Volume

1.85M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

11.2%

Avg Negative

48.4%

Avg Neutral

40.4%

News Feed

Immunovant, Inc. (IMVT) Up 6.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research·7/1/2021·↓ negative

Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4

Zacks Investment Research·6/2/2021·↑ positive

IMVT Stock Price: Over 20% Decrease Pre-Market Explanation

Pulse2·6/1/2021·↓ negative

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021

GlobeNewsWire·6/1/2021·↑ positive

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

PRNewsWire·4/20/2021·↓ negative

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp·4/19/2021·↓ negative

IMVT Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Immunovant, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 20, 2021

Newsfile Corp·4/18/2021·↓ negative

SHAREHOLDER ALERT: Holzer & Holzer Encourages Immunovant Investors With Significant Losses to Contact the Firm

Newsfile Corp·4/16/2021·↓ negative

TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile Corp·4/16/2021·↓ negative

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Business Wire·4/15/2021·↓ negative